Abstract
Translating Visual Short-Term Memory Binding Tasks to Clinical Practice: From Theory to Practice.
Highlights
Alzheimer’s disease (AD) is the most common form of neurodegenerative dementia, accounting for 2/3 of all dementia cases and currently recognized as a global public health challenge
Crucial to clinical practice is the transition from (a) the initial confirmation of association with the outcome of interest (e.g., visual shortterm memory (VSTM) binding impairment is associated with a diagnosis of AD) to (b) acquiring sensitivity to a treatment or an intervention (e.g., VSTM binding deficits decline in response to a therapy) and (c) showing a “meaningful” change in patient behavior [41]
The recent Food and Drug Administration guidelines suggest that biomarkers alone will not be sufficient as surrogate outcomes to show effectiveness of treatment [44]
Summary
Alzheimer’s disease (AD) is the most common form of neurodegenerative dementia, accounting for 2/3 of all dementia cases and currently recognized as a global public health challenge. One important line of AD research in the last decade has provided evidence that the ability to bind object features together in short-term memory (STM) is affected in AD even at asymptomatic stages [3, 4]. STM binding is a cognitive function known to support the integration of features necessary to maintain a coherent representation of an object in immediate memory.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
